La Jolla Pharma beats by $0.07
- Reports Q3 (Sep) loss of $1.19 per share, $0.07 better than the Capital IQ Consensus of ($1.26).
- The San Diego-based company reported a loss of $26.3 million in its third quarter.
- As of September 30, 2017, the Company had $120.8 million in cash and cash equivalents, compared to $65.7 million of cash and cash equivalents at December 31, 2016. Cash used in operating activities for the nine months ended September 30, 2017 was $60.4 million, compared to $40.1 million for the same period in 2016.
No comments:
Post a Comment